Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 62

Results For "Safety"

1765 News Found

India releases first-ever National Guidelines/SOPs for animal blood transfusion and blood banks
News | August 26, 2025

India releases first-ever National Guidelines/SOPs for animal blood transfusion and blood banks

Guidelines aim to establish state-regulated veterinary blood banks


Terumo India launches Terufusion advanced infusion systems in India
News | August 26, 2025

Terumo India launches Terufusion advanced infusion systems in India

Terufusion Advanced Infusion Systems combine a smart syringe pump, smart infusion pump, and pump monitoring system software for precise and efficient drug administration


GSK forays into oncology in India with Jemperli and Zejula
News | August 25, 2025

GSK forays into oncology in India with Jemperli and Zejula

The company is bringing precision therapies for gynaecological cancers


AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib
News | August 23, 2025

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study


Vivo Bio Tech secures pre-clinical testing contract valued at Rs.10.75 Cr
News | August 22, 2025

Vivo Bio Tech secures pre-clinical testing contract valued at Rs.10.75 Cr

Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies


FDA lifts hold on Rocket Pharma's gene therapy trial
News | August 22, 2025

FDA lifts hold on Rocket Pharma's gene therapy trial

Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort


BioAge Labs doses first patient in BGE-102 phase 1 trial
Biotech | August 19, 2025

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants


Sarepta advances siRNA collaboration and sale of arrowhead equity investment
News | August 19, 2025

Sarepta advances siRNA collaboration and sale of arrowhead equity investment

Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation